ABSTRACT OF THE DISCLOSURE
The present invention relates to new heterocyclic com pounds and processes for their production.
The present invention provides compounds of general Formula I, 4 . pH E. The present invention further provides the following processes for the production of compounds of general Formula I:
(a) Compounds of general Formula I are obtained by reacting a salt of a compound of general Formula II, II. in which R2, R3 and R4 have the above significance, The compounds of general Formula I obtained in ac cordance with the above precesses are then optionally con verted into their acid addition salts with inorganic or or ganic acids. Suitable reactive, functional derivatives of acids of gen eral Formula III, which may be used in the condensation of the invention in accordance with process (a) , are their mixed anhydrides with sulphuric acid, their azides and, preferably, their acid chloride hydrochlorides. Ex amples of suitable solvents which are inert under the re action conditions are dimethyl formamide, acetonitrile, methylene chloride and chloroform, and examples of suitable basic condensation agents are particularly teriary organic bases, e.g. pyridine or trimethylamine, and weak inorganic bases, e.g. alkali metal carbonates, pyridine be ing preferred. The function of the basic condensation agent is a rather complicated one and may include one or more of the following depending on the particular re active functional acid derivative used: (a) Liberation of aminocyclol of Formula II from its salt, (b) binding of acid liberated in the condensation, (c) complex formation and (d) a solvent function. The reaction is effected at a temperature between about -20° and -30° C., depending on the type of functional, reac tive acid derivative used. Preferred temperatures for par ticular reactive functional acid derivatives are indicated below. In general the particular temperature adopted depends on a compromise between a low temperature favouring reduction of the tendency of the free amino cyclol of Formula II to rearrange and a higher tempera ture favouring the reactivity of the acid derivative. The compounds of general Formula II are used in the conden sation of the invention in the form of their salts, as the compounds of general Formula II are unstable in the free form. Examples of acids which are sufficiently strong to form salts include hydrochloric, hydrobromic, sulphuric, Oxalic, maleic, methanesulphonic and tartaric acid. The preferred salt is the hydrochloride.
One preferred method of effecting the process of the invention consists in that an acid chloride hydrochloride of an acid of general Formula III is reacted with a salt of a compound of general Formula II indicated above, e.g. in methylene chloride suspension, while cooling to about -10° to 0° C., in the presence of a tertiary organic base, e.g. pyridine. The reaction mixture is then optionally allowed to stand at room temperature for some time in order to complete the reaction. After the reaction is completed the resulting compound of general Formula I is isolated from the reaction mixture in manner known per se, e.g. by diluting with the same or another solvent, washing the solution with basic wash solutions and sub sequently with water, drying and concentrating the solu tion by evaporation and subjecting the residue to chro matography. Another method of effecting the condensation of the invention is as follows: The mixed anhydride of an acid of general Formula III with sulphuric acid is condensed at -10° to 0° C. in a solvent which is inert under the re action conditions, e.g. dimethyl formamide, and in the presence of a tertiary organic base, e.g. pyridine, with a compound of general Formula II, which is used in the form of a salt indicated above, and the resulting compound of general Formula I is isolated from the reaction mix ture and purified in manner known per se.
In accordance with another embodiment of the process of the invention the condensation is effected by reacting a solution of an azide of an acid of general Formula III, e.g. in the presence of a tertiary organic base, at a temperature of about 0° C. to room temperature (20 C.), in a solvent which is inert under the reaction condi tions, with a compound of general Formula II in the form of a salt.
For the best yields, the basic condensation agent should be added slowly to the reaction mixture.
Hydrogenation of compounds of general Formula Ib may be effected catalytically or with an alkali metal in liquid ammonia.
Catalytic hydrogenation is effected in a solvent which is inert under the reaction conditions, e.g. ethanol, or a solvent mixture, e.g. ethanol/methylene chloride, prefer ably at room temperature and normal pressure, but this hydrogenation may also be effected at an elevated tem perature or pressure. Of the usual hydrogenation cata lysts the palladium catalysts are especially suitable, par ticularly palladium on a carrier such as aluminium oxide.
After the taking up of hydrogen is completed the reaction mixture is worked up, for example by filtering off the catalyst and isolating the final product from the filtrate and purifying in manner known perse.
The methylation of the invention in accordance with process (c) is effected using as strong bases preferably alkali metal alcoholates and alkali metal amides, and as Solvent which is inert under the reaction conditions liquid ammonia, or a lower amine.
One preferred method of effecting this methylation process consists in adding portionwise metallic sodium or potassium to a solution of a lower aliphatic alcohol, e.g. ethanol, in liquid ammonia, and wating for the de colouration of the solution to occur. The compound to be methylated is added to the resulting suspension of the metal alcoholate at about -40° C. while stirring well, and after the solution has occurred methyl iodide is added. The ammonia is subsequently evaporated off in a vacuum and the residue divided between an aqueous alkali metal carbonate solution and methylene chloride, the organic phase is washed with water, dried over sodium Sulphate and the methylene chloride is removed.
About 5 mols of an alkali metal alcoholate or 1.5 to 2.0 mols of an alkali metal amide and about the same excess of methyl iodide are preferably used in this re action for every mol of the compound to be methylated.
The new alkaloids of general Formula I produced in accordance with the invention are crystalline compounds at room temperature and with inorganic or strong organic acids form stable salts which are crystalline at room tem perature. Examples of acids for salt formation are min eral acids such as hydrochloric, hydrobromic or sulphuric acid, strong organic acids such as tartaric acid, oxalic acid or methanesulphonic acid.
The compounds of general Formula Ib are named with trivial names in a manner analogous to that of other al ready known ergot peptide alkaloids, or with designated 3,586,683 The alkaloids of general Formula Ia are named with the prefix 9,10-dihydro, followed by the trivial name. In the compounds of general Formula Ic the prefix "1-methyl' is placed before the name.
It should be noted that the compounds of the present application represent a completely new type of com pound. They are not able to occur in nature because the aminoacids necessary for the biosynthesis of the relevant portion of compounds of Formula II (shown below in Formula II) do not occur in nature. The said aminoacids are of the ox, ox-disubstituted type which are purely Syn thetic products.
A.
The compounds of Formula I and their acid addition salts possess pharmacological activity in animals. They are particularly useful as vasotonic agents as indicated by the vasopressor action in the spinal cat preparation method of Barger G. and H. H. Dale, J., Physiol. (L) 41, 19 (1910) . In this test dosages as low as 0.8/pg./kg. have been found to be effective, thus indicating that the compounds are very active.
For the above-mentioned use, the dosage administered will, of course, vary depending upon the compound em ployed, mode of administration and treatment desired. For large mammals, satisfactory results are, for example, obtained by administering a total daily dose of from about 1 to 50 ug./kg. orally.
The compounds I and their acid addition salts are to be used in similar manner and for the same purposes as ergotamine and 9,10-dihydroergotamine (e.g. in the treat ment of migraine and other vascular headaches, etc.) ex cept that they are more specific (in particular their adren anil-like activity is considerably lowered).
As in the case of ergotamine, the compounds have been The preparations may furthermore contain suitable pre serving, stabilizing and wetting agents, solubilizers, sweet ening and colouring substances, and flavourings.
The compounds of general Formula II used as starting materials are new, are only stable in the form of their salts, and their production also forms part of the present invention.
The compounds of general Formula II are produced in accordance with the invention by splitting off the benzyl oxycarbonyl radical from a compound of general For mula IV, H . gh < S-cr-0. --N:
in which R2, R3 and R4 have the above significance, in acid solution. The benzyloxycarbonyl protective rad ical of the urethanes of general Formula IV is preferably split off hydrogenolytically in an inert solvent, e.g. tetra hydrofuran, in which a mineral acid has been dissolved, whereby the salts of the compounds of general Formula II are obtained. this is saponified to a compound of general Formula XIV, this is converted into an acid chloride of general Formula XV, the compound of general Formula XV is reacted with sodium azide to give a compound of general For mula XVI, and this is converted into a benzyl urethane of general Formula IV by reacting with benzyl alcohol at an elevated temperature in a solvent which is inert under the reaction conditions.
The amino acids of general Formula VII are produced by reacting a ketone of general Formula V in accordance with Strecker's synthesis with an alkali metal cyanide and an ammonium salt, optionally in a solvent or solvent mix ture which is inert under the reaction conditions, and saponifying the resulting aminonitrile of general Formula VI, preferably with a mineral acid. When the amino acids of general Formula VII have an asymmetric structure, they are advantageously separated into their optical an tipodes via a salt with a strong, optically active acid, and their absolute configuration is deduced in manner known per se. Thus, for example, the racemic ox-methylphenyl alanine, obtained in accordance with Strecker's synthesis from benzylmethylketone, may be converted with (--)-camphor-10-sulphonic acid into a mixture of the two di astereoisomeric salts, which may be separated by crystal lization. The splitting of the more difficultly soluble salt, e.g. with an ion exchange resin, yields the isomer with positive rotation in water, the absolute configuration of which may be deduced from the comparison of its rota tion values with those of S-phenylalanine and from the rotation values of the diketopiperazine synthesized there from with S-proline.
The compounds of general Formula VII are converted into the amino acid esters of general Formula VIII in a lower alcohol with a mineral acid, e.g. hydrochloric acid. Their acylation with (2S)-N-benzyloxycarbonylpro line to give dipeptides of general Formula IX is effected using a reagent suitable for the production of peptide link ages, e.g. mixed acid anhydrides or ethoxyacetylene, pref erably, however, using dicyclohexylcarbodiimide in a sol vent or solvent mixture which is inert under the reaction conditions.
Since the compounds of general Formula IX often only crystallize with great difficulty, they are catalytically hy drogenated in crude state, whereby the carbobenzoxy pro tective radical is removed. The resulting dipeptide esters of general Formula X, which are free at the amino end, often react spontaneously to give pyrroloI1,2-alpyrazines of general Formula XI. If this spontaneous reaction does not occur, they may be readily cyclized by heating, op tionally with an acid or basic catalyst.
The pyrrolol,2-alpyrazines of general Formula XI are Subsequently acylated with a 2-benzyloxymalonic acid monoethyl ester of general Formula XVII in the presence of a tertiary amine, e.g. pyridine or N-ethyldiisopropyl amine, and in a solvent which is inert under the reaction conditions, e.g. dioxane, preferably at a temperature of -10 to --90 C., to give compounds of general Formula XII. The O-benzyl radical is then removed hydrogenolyti cally from the compound of general Formula XII in a solvent or solvent mixture which is inert under the reac tion conditions, e.g. ethyl acetate, methanol, ethanol or glacial acetic acid/water, preferably using a prehydro genated palladium catalyst, whereupon spontaneous 3,586,683 cyclization occurs to give a compound of general Formula XIII.
The ester radical of the thus obtained compound of general Formula XIII is subsequently converted into the amino radical, preferably as follows: the compound of general Formula XIII is saponified to a free acid of gen eral Formula XIV by the action of a dilute, aqueous/ alcoholic lye or dilute lye in a solvent which is inert under the reaction conditions, e.g. dioxane, at room tempera ture, the free acid of general Formula XIV is subsequently converted into the corresponding acid chloride of general Formula XV with phosphorus pentachloride in a solvent which is inert under the reaction conditions, e.g. ether.
The production of the acid chloride of general Formula XV may likewise be effected via an alkali metal salt of the carboxylic acid of general Formula XIV with oxalyl chloride. Reaction of the acid chloride of general Formula XV, dissolved in an inert solvent, e.g. methylene chloride, with a concentrated, aqueous solution of sodium azide at room temperature then leads to the fairly unstable acid azide of general Formula XVI. The urethane of general Formula IV is obtained via the isocyanate result ing as intermediate by heating the acid azide with a small excess of benzyl alcohol in an inert solvent, e.g. chloro form, to the boil for a short period, with nitrogen evolution.
Insofar as the production of the starting materials re quired is not described, these are known or may be pro duced in manner known perse or in a manner analogous to that described in the examples. (Of course, the start ing materials of Formula Ib and Id used in methods (b) and (c) may be obtained by method (a) using appropriate starting materials.)
The term "in manner known per se" as used herein designates methods in use or described in the literature on the subject.
In (b) 1-aminocyclohexane-1-carboxylic acid-121 g. of 1-amino-1-cyano-cyclohexane are added dropwise while stirring and cooling during the course of 15 minutes to 1.5 liters of concentrated hydrochloric acid, and the mix ture is stirred at room temperature over night, 1.5 liters of water are added and heating to the boil at reflux is effected for 2 hours. After cooling the reaction mixture is filtered through active charcoal and the filtrate is dried.
The residue is dissolved in 1.5 liters of concentrated am monia solution while heating and is subsequently con centrated to about one third of its initial volume, whereby the crude amino acid crystallizes. After recrystallization from water pure 1-aminocyclohexane-1-carboxylic acid, having a M.P. of 320 (decomp.) is obtained in the form of colourless rectangular leaflets. (h) (2R, 10'aS,10'bS) -2'-chloroformyl-3,6'-dioxo 10b -hydroxy-2'-methyloctahydrospiro cyclohexane-1,5' (8H)-oxazolo 3,2-alpyrroloI2,1-c pyrazine) -7.3 g. of freshly sublimated phosphorus pentachloride are stirred in a mixture of 50 cc. of absolute ether and 100 cc. of abso lute petroleum ether for 2 hours, whereby the phosphorus pentachloride dissolves almost completely. 5.9 g, of finely pulverized, high vacuum dried (2R,10'aS,10"bS)-2'-car boxy -3,6'-dioxo-10b-hydroxy-2-methyloctahydrospiro cyclohexane -1,5'(8H) -oxazolo 3,2-alpyrrolo[2,1-cl pyrazine) are then added and the mixture is stirred at 3,586,683 13 been dissolved, are hydrogenated with 3 g. of prehydro genated palladium/active charcoal catalyst (5% Pd) at room temperature until the taking up of hydrogen is com pleted (about 20 minutes, amount of hydrogen taken up 145 cc.). After filtering off the catalyst and the partially crystallizing (2R,10'aS,10'bS) -2 -amino -3,6-dioxo 10b-hydroxy-2' -methyloctahydroSpirocyclohexane -1, 5 (8H)-oxazolo(3,2 -a pyrrolo2, 1 -clpyrazine) hydro chloride, the tetrahydrofuran solution is concentrated almost to dryness in a vacuum at 20, the residue is com bined with the methanol eluate of the catalyst (in which the (2'R,10'aS,10bS)-2'-amino -3,6'-dioxo -10b -hy droxy-2-methyloctahydrospirocyclohexane -1,5' (8H)-oxazolo 3,2-alpyrrolo2,1-c) pyrazine) which crystallizes during hydrogenation, has been dissolved), the methanolic solution is again concentrated to about 15 cc. at a bath temperature of 20 in a vacuum and (2R, 10'aS, 10'bS)-2'-amino-3,6'-dioxo-10b-hydroxy -2 -methyloctahydro spirocyclohexane -1,5" (8'H) -oxazolo 3,2 -alpyrrolo I2,1-c) pyrazine hydrochloride is made to crystallize by the addition of absolute ether. A crystalline powder, having a M.P. of 161-162 (decomp.), is obtained.
(1) Ergospironine-2.0 g. of (2R,10'aS, 10'bS)-2'-amino-3',6'-dioxo-10'b-hydroxy -2 -methyloctahydro spiro (cyclohexane -1,5'(8H) -oxazolo (3,2 -alpyrrolo 2,1-cpyrazine hydrochloride and 3.75 g. of d-lysergic acid chloride hydrochloride are suspended in 70 cc. of absolute methylene chloride, the suspension is cooled to -10 and 30 cc. of absolute pyridine are subsequently added dropwise while stirring during the course of 5 minutes. The reaction mixture is allowed to react for half an hour in an ice bath and subsequently at 20 for Formula XVIII, c . y-CH-ce 2.2g. of ergospironine in 50 cc. of undenatured alcohol and 20 cc. of methylene chloride are hydrogenated with 1 g. of palladium/aluminium oxide catalyst at room tem perature and normal pressure until the taking up of hydro gen is completed (about 2 hours, amount of hydrogen taken up 90 cc.). After filtering off the catalyst, the fil trate is sucked off to dryness and the residue recrystallized from ethanol, whereby 9,10-dihydroergospironine is ob After removing the dicyclohexyl urea which crystallizes the filtrate is successively extracted with 2 N sulphuric acid, water, a potassium carbonate solution and again with Water, the aqueous phases are shaken out twice more with ether, the combined ether solutions are dried and con centrated by evaporation. The residue of (2S)-1-(benzyl Oxycarbonyl) -N -(1-methyl-1-ethoxycarbonyl)ethyl-2-pyrrolidinecarboxylic acid amide does not crystallize and is further Worked up as crude product. For this purpose 320 g. of (2S)-1-(benzyloxycarbonyl) -N -(1-methyl-1-ethoxycarbonyl)ethyl-2-pyrrolidinecarboxylic acid amide in 1.6 liters of ethyl acetate are hydrogenated with 65 g. of prehydrogenated palladium/active charcoal catalyst (5% Pd) at room temperature and normal pressure. After the taking up of hydrogen has been completed, the catalyst is filtered off and the solvent is evaporated, whereby a yel low viscous oil, mainly consisting of (2S)-N-(1-methyl-1-ethoxycarbonyl)ethyl-2-pyrrolidinecarboxylic acid amide, is obtained; as this cannot be crystallized, it is cyclized as crude product to give (8aS) liter of undenatured alcohol and is catalytically hydro genated with 25 g. of prehydrogenated palladium/active charcoal catalyst (5% Pd) at normal pressure and a tem perature of 45. After 7.3 liters of hydrogen have been taken up during the course of 18 hours, hydrogen is no longer taken up, so that the catalyst is filtered off and the Solvent removed in a vacuum. After crystallization from diisopropyl ether the residue yields (2R,10aS, 10bS)-2-ethoxycarbonyl-3,6-dioxo-10b-hydroxy -2,5,5-trimethyl octahydro-8H-Oxazolo 3,2-alpyrrolo[2,1-c]pyrazine hav ing a M.P. of 108-111 and a mother liquor which yields a further amount of (2R,10aS,10bS) -2 -ethoxycarbonyl 3,6-dioxo -10b -hydroxy-2,5,5-trimethyl-octahydro-8H Oxazolo 3,2-alpyrrolo[2,1-clpyrazine, having a M.P. of 109-111, after filtration through a 5-fold quantity of aluminium oxide, activity I. A sample of this compound is recrystallized from diisopropyl ether until the M.P. is constant. M.P. 111-113, prisms joined in druses, Iol D= --42.7 (c. = 1, ethanol), pKics=10.8.
(e) (2R,10aS, 10bS) -2 -carboxy -3,6 -dioxo-10b hydroxy-2,5,5-trimethyloctahydro -8H-oxazolo(3,2-al pyrrolo[2,1-c]pyrazine-69 g, of (2R,10aS,10bS) -2 ethoxycarbonyl -3,6 -dioxo -10b -hydroxy -2,5,5-tri methyloctahydro -8H -oxazolo 3,2-alpyrrolo[2,1-clpyr azine are dissolved at 0 in 210 cc. of a 2 N sodium hy droxide solution, whereby the temperature rises to 20.
After standing at 20 for 2 hours the somewhat turbid solution is filtered through active charcoal and the pH of the resulting clear and colourless solution is adjusted to 1.5 with about 105 cc. of 4 N hydrochloric acid, whereby (2R,10aS,10bS) -2 -carboxy-3,6-dioxo-10b-hydroxy 2,5,5 -trimethyloctahydro-8H-oxazolo 3,2-alpyrrolo2, 1 cl pyrazine immediately starts to crystallize. After cooling to 0 the crystalline precipitate is filtered off, washed with water and dried in a high vacuum at 20, whereby (2R, 10aS, 10bS)-2-carboxy-3,6-dioxo -10b -hydroxy-2,5, 5-trimethyloctahydro -8H -oxazolo 3,2-alpyrrolo 2,1-c. pyrazine, having a M.P. of 146-147 (decomp.), is ob tained. The mother liquor is reduced to half its volume, 10% common salt is dissolved therein and the solution is again made to crystallize in an ice bath, whereby a further amount of (2R, 10aS, 10bS)-2-carboxy-3,6-dioxo (f) (2R,10aS,10bS) -2 -chloroformyl-3,6-dioxo-10b hydroxy -2,5.5 -trimethyloctahydro -8H -oxazolo 3,2-alpyrrolo2,1-c]pyrazine-20.8 g. of freshly sub limated, finely pulverized phosphorus pentachloride are dissolved in 250 cc. of absolute ether at 25-35, 125 cc. of absolute petroleum ether are added to the solution and cooling is effected to --5. 14.9 g. of high vacuum dried, finely pulverized (2R,10aS,10bS) -2 -carboxy-3,6-dioxo 10b -hydroxy -2,5,5 -trimethyloctahydro-8H-oxazolo I3,2-alpyrrolo[2,1-c)pyrazine are then added to the solu tion and the mixture is stirred in an ice bath for 2/2 hours. The (2R, 10aS,10bS) -2 -chloroformyl-3,6-dioxo 10b -hydroxy -2,5,5--trimethyloctahydro-8H-oxazolo 3,2-alpyrrolo2, 1-c) pyrazine which crystallizes is filtered off, is again washed with 100 cc. of a mixture of ether/ petroleum ether in a ratio per volume of 1:1 and is dried in a high vacuum at 20, whereby the crude acid chlo ride, having a great liability to decomposition and a M.P. of absolute ether, whereby the azide rapidly crystallizes. After cooling of 0 filtration is effected, the precipitate is washed well with absolute ether and dried in a high vacuum at 20, whereby (2R,10aS,10bS)-2-azidocarbon yl) -3,6-dioxo -10b-hydroxy-2,5,5-trimethyloctahydro 8H-oxazolo 3,2-alpyrrolo2,1-c]pyrazine, having a M.P. of 105 (decomp.), ox20= -41 (c. =1.7, methylene chloride), is obtained.
(h) (2R,10aS,10bS) -2 -benzyloxycarbonylamino-3,6-dioxo-10b-hydroxy-2,5,5 -trimethyloctahydro-8H-oxazolo (3,2-alpyrrolo,2,1 -clipyrazine. -13.2 g. of (2R, 10aS, 10bS) -2 -azidocarbonyl-3,6-dioxo-10b-hydroxy-2,5,5-trimethyloctahydro -8H -oxazolo (3,2-alpyrrolo2, 1-c. pyrazine are dissolved in 130 cc. of absolute chloroform, 8.9 g, of absolute benzyl alcohol are added and the mix ture is heated to the boil at reflux for 30 minutes. The chloroform is then removed and the crystalline residue is recrystallized from ethanol, whereby some impure (2R, 10aS,10bS) -2 -benzyloxycarbonylamino-3,6-dioxo 10b -hydroxy -2,5,5 -trimethyloctahydro-8H-oxazolo 3,2-alpyrrolo[2,1-clpyrazine is obtained, which is ob tained in pure form after crystallizing once more from ethanol/hexane. Colourless needles having a M.P. of 232 233 (decomp.), ox)20= --47.2° (c. =1, ethanol).
(i) (2R, 10aS,10bS)-2-amino-3,6-dioxo -10b -hydroxy 25,5-trimethyloctahydro -8H -oxazolo 3,2-alpyrrolo 2, 1-c)pyrazine hydrochloride.-5 g. of palladium chloride are hydrogenated in 100 cc. of absolute tetrahydrofuran in which 128 mg. of gaseous hydrochloric acid has been dissolved, until the taking up of hydrogen is completed (about 20 minutes, amount of hydrogen taken up 850 cc.). A solution of 16 g. of (2R, 10aS, 10bS)-2-benzyloxycar bonylamino -3,6 -dioxo -10b-hydroxy-2,5,5-trimethyl octahydro -8H -oxazolo 3,2-alpyrrolo2,1-cpyrazine in 250 cc. of absolute tetrahydrofuran is added to the so prepared suspension of the catalyst and hydrogenation is effected at room temperature and normal pressure. 800 cc. of hydrogen are taken up in the course of 80 minutes, the reaction is completed and most of the (2R,10aS,10bS)-2-amino -3,6 -dioxo -10b-hydroxy-2,5,5-trimethylocta hydro -8H -oxazolo (3,2-alpyrrolo[2,1-c pyrazine hy drochloride crystallizes. After allowing the reaction mix ture to stand in an ice bath filtration is effected, the precipitate is washed with ether and dried at 20 in a high vacuum, whereby a grey powder results, which con sists of metallic palladium and (2R, 10aS,10bS) (2S,oS)-N-(o-methyl -c. -methoxycarbonyl)phenethyl 2-pyrrollidinecarboxylic acid amide is cyclized to (3S,8aS)-3-benzyl-1,4-dioxo-3-methyloctahydropyrrolo.1,2-alpyra zine by adding 2 cc. of glacial acetic acid to the crude product and heating to 120 in a vacuum for 1 hour. After about 45 minutes (3S,8aS)-3-benzyl-1,4-dioxo-3-methyloctahydropyrrolo.1,2-apyrazine already starts to crystallize. This crude product is further purified by crys tallization from ethyl acetate/isopropyl ether, whereby fine needles having a M.P. of 159-161, are obtained. A further amount of (3S,8aS)-3-benzyl-1,4-dioxo-3-meth yloctahydropyrroloI1,2-alpyrazine may be obtained from the mother liquors; this may be combined with the first fraction, and after recrystallizing once more from ethyl acetate/isopropyl ether, yields pure lactam having a M.P. (e) (3H,8aS,oS) -2 -(o-ethoxycarbonyl-o-benzyloxy propionyl)-3-benzyl -14 -dioxo-3-methyloctahydropyr rolo.1,2-alpyrazine.-40 g. of (3S,8aS)-3-benzyl-1,4-di oxo-3-methyloctahydropyrroloI1,2-alpyrazine are added to 25 cc. of absolute dioxane and 16 cc. of absolute pyr idine and the mixture is cooled to 10°. 46 g. of S(--)-2-methyl-2-benzyloxy-malonic acid chloride monoethyl ester are then added dropwise at 10 while stirring dur ing the course of 10 minutes and the mixture is stirred at 20 for 1 hour and then at 60° for 4 hours. Working up is effected by cooling the mixture to 10 and adding an excess of ice-cold dilute phosphoric acid. Immediately thereafter extraction is effected thrice with ether, the com bined ether solutions are successively washed with wa ter, a saturated sodium hydrogen carbonate solution and again water, the ether solutions are dried with sodium sulphate and the solvent removed. After crystallizing once from diisopropyl ether the crystalline residue yields (3S,8aS,0S) -2 -(o-ethoxycarbonyl-o-benzyloxypropio nyl)-3-benzyl-1,4-dioxo -3 -methyloctahydropyrrolo.1,2- (2R,5S,10aS,10bS) -5 -benzyl-2-carboxy-2,5-dimethyl 3,6-dioxo -10b -hydroxyoctahydro-8H-oxazolo 3,2-a pyrrolo2,1-cpyrazine dihydrate has a M.P. of 143 (decomp.). After recrystallization from acetone until a constant M.P. is obtained (2R,5S,10aS,10bS) -5 -benzyl 2-carboxy-2,5-dimethyl -3,6 -dioxo -10b -hydroxyocta hydro -8H -oxazolo (3,2-alpyrrolo[2,1-c]pyrazine mono hydrate has a M.P. of 144 (decomp.), ox20=-|-65° 5S,10aS,10bS )-5-benzyl -2 -chloroformyl-2,5-dimethyl-3,6-dioxo-10b hydroxyoctahydro -8H -oxazolo 3,2-alpyrrolo2,1-c. pyrazine starts to crystallize. After stirring for half an hour 125 cc. of absolute petroleum ether are added to the reaction mixture and stirring is again effected for half an hour in an ice bath. After filtering off the acid chloride which crystallizes, this is washed well with petroleum ether, and dried at 20, whereby (2R,5S,10aS,10bS)-5-benzyl-2-chloroformyl-2,5-dimethyl -3,6-dioxo-10b-hy droxyoctahydro -8H -oxazolo 3,2-alpyrrolo[2,1-clpyr azine, having a M.P. of 126-127 (decomp.), is obtained.
The combined filtrates are strongly concentrated in a vac 3,586,683 2. uum, whereby a second fraction of (2R,5S,10aS,10bS)-5-benzyl-2-chloroformyl -2,5 -dimethyl -3,6 -dioxo-10b hydroxyoctahydro -8H -oxazolo 3,2-alpyrrolo2,1-c. pyrazine is obtained. Iox)= --64 (c. = 0.2 in methylene chloride).
(i) (2R,5S,10aS,10bS) -2 -azidocarbonyl -5 -benzyl 2,5 -dimethyl-3,6-dioxo -10b -hydroxyoctahydro-8H Oxazolo 3,2-alpyrrolo2,1-c]pyrazine.-A solution of 4.46 g. of (2R,5S, 10aS,10bS) -5 -benzyl-2-chloroformyl-2,5-dimethyl -3,6 -dioxo -10b -hydroxyoctahydro-8H-oxa Zolo.3,2-alpyrrolo2,1-cpyrazine in 45 cc. of absolute chloroform is cooled to 0 and a solution of 1.85 g. of Sodium azide in 5 cc. of water is added while mixing vigorously with a vibro-stirrer, whereby the temperature rises to --5. After mixing for a further 5 minutes 10 cc. of a 20% potassium hydrogen carbonate solution are add ed, mixing is effected for a further minute, the organic phase is separated and the aqueous phase is extracted twice with 50 cc. each of absolute methylene chloride. The chloroform solution and the two methylene chloride (k) (2R,5S,10aS,10bS) -2 -amino -5 -benzyl-2,5-dimethyl-3,6-dioxo-10b-hydroxyoctahydro -8H -oxazolo 3,2-alpyrrolo2, 1-cpyrazine hydrochloride.-565 mg. of anhydrous palladium chloride are suspended in 10 cc. of absolute tetrahydrofuran containing 200 mg. of gaseous hydrochloric acid and prehydrogenation is effected as long as a taking up of hydrogen is still observed. A solu tion of 2.0 g. of (2R,5S,10aS,10bS) -5 -benzyl-2-benzyl Oxycarbonylamino-2,5-dimethyl-3,6-dioxo-10b-hydroxy Octahydro-8H-oxazolo (3,2-alpyrrolo2,1-clpyrazine in 50 cc. of tetrahydrofuran is added to the suspension of the resulting palladium and hydrogenation is effected at room temperature. After hydrogenating for 1 hour 60 cc. of hy drogen have been taken up and the reaction is completed. In order to crystallize the resulting (2R,5S,10aS,10bS)-2-amino -5 -benzyl -2,5 -dimethyl -3,6 -dioxo-10b hydroxyoctahydro -8H -oxazolo 3,2-alpyrrolo[2,1-cpyrazine hydrochloride as completely as possible, the re action mixture is Subsequently kept in an ice bath for 45 minutes, whereby after filtering and carefully drying in a vacuum a grey powder is obtained, consisting of (2R,5S, 10aS, 10bS)-2-amino -5 -benzyl-2,5-dimethyl-3,6-dioxo 10b -hydroxyoctahydro -8H -oxazolo 3,2-alpyrrolo 2,1-c pyrazine hydrochloride and metallic palladium. Af ter recrystallization from tetrahydrofuran/ether the mother liquor yields a further amount of (2R,5S, 10aS, 10bS)-2-amino -5 -benzyl -2.5 -dimethyl-3,6-dioxo-10b
hydroxyoctahydro -8H -oxazolo 3,2-alpyrroloL2,1-c. (1) 5'-methyl-9,10-dihydroergotamine.-A mixture of 40 cc. of absolute acetonitrile and 50 cc. of absolute di methylformamide is cooled to -15°, 9 g. of 9,10-dihydro lysergic acid chloride hydrochloride are added and 40 cc. of absolute pyridine are added dropwise at -15 while stirring during the course of 5 minutes, whereby a thick, brown mash is formed. 5.28 g. of (2R,5S, 10aS, 10bS)-2-amino-5-benzyl-2,5-dimethyl-3,6-dioxo -10b -hydroxy octahydro -8H -oxazolo 3,2-alpyrrolo[2,1-c]pyrazine hydrochloride are then added to this mixture, and the reaction mixture is further stirred for 1% hours, whereby the temperature is gradually allowed to rise to 0. For purposes of working up the reaction mixture is poured into 150 cc. of 2 N hydrochloric acid which contains approximately the same amount of ice, the mixture is (d) (2R,5S,10aS, 10bS) -5-benzyl-2-benzyloxycarbon ylamino-3,6-dioxo-10b-hydroxy-2-isopropyl -5 -methyl octahydro -8H -oxazolo 3,2-alpyrrolo[2,1-c) pyrazine.--9.5 g. of (2R,5S,10aS,10bS)-2-azidocarbonyl-5-benzyl-3, 6-dioxo-10b-hydroxy-2-isopropyl-5-methyloctahydro -8H oxazolo 3,2-alpyrrolo2,1-cpyrazine are dissolved in 50 cc. of absolute chloroform, 4.0 g. of absolute benzyl al cohol and 1 drop of concentrated hydrochloric acid are added and the mixture is heated to the boil at reflux for half an hour. After removing the chloroform in a vacuum the residue is dissolved in a mixture of methylene chloride and ethyl acetate, active charcoal is added, filtration through Hyflo and dilution with ether are effected, where by (2R,5S, 10aS, 10bS) -5 -benzyl -2 -benzyloxycarbon ylamino -3,6 -dioxo -10b-hydroxy-2-isopropyl-5-methyl octahydro -8H -oxazolo 3,2-alpyrrolo2,1-cpyrazine crystallizes in the form of prisms joined in druses, having t M.P. of 212 (decomp.), ox20=-|-38 (c.-1, pyri ine).
(e) (2R,5S,10aS,10bS) -2 -amino -5 -benzy -3,6-dioxo -10b -hydroxy -2 -isopropyl-5-methyloctahydro 8H -Oxazolo 3,2 -alpyrrolo 2,1 -cpyrazine hydrochlo ride-4 g. of anhydrous palladium chloride are suspended in 50 cc. of absolute dimethyl formamide containing 1 g. of gaseous hydrochloric acid and prehydrogenation is effected as long as a taking up of hydrogen is observed. A Solution of 9.5 g. of (2R,5S,10aS,10bS)-5-benzyl-2-benzyloxycarbonylamino -3,6 -dioxo -10b -hydroxy-2-isopropyl -5 -methyloctahydro -8H -oxazolo 3,2 -a pyrroloI2,1-c pyrazine is added to the suspension of the resulting palladium and hydrogenation is effected at room temperature. After a hydrogenation period of 10 minutes 480 cc. of hydrogen have been taken up and the reaction is completed. The catalyst is removed by filtration and the filtrate evaporated to dryness. After recrystallization from tetrahydrofuran/ether (2R,5S, 10aS,10bS)-2-amino 5 -benzyl-3,6-dioxo -10b-hydroxy-2-isopropyl-5-meth yloctahydro -8H -oxazolo (3,2-alpyrrolo[2,1-c]pyrazine hydrochloride, having an M.P. of 112 (decomp.), is ob tained.
(f) 5'-methyl-9,10-dihydroergocristine.-A mixture of 40 cc. of absolute acetonitrile and 50 cc. of absolute di methyl formamide is cooled to -15, 9 g. of 9,10-dihy drolysergic acid chloride hydrochloride are added and 40 cc. of absolute pyridine are added dropwise at -15 while stirring during the course of 5 minutes, whereby a thick, brown mash is formed. 6.0 g. of (2R,5S, 10aS, 10bS) -2 -amino -5 -benzyl -3,6-dioxo-10b-hydroxy 2 -isopropyl -5 -methyloctahydro -8H-Oxazolo 3,2-al 3,586,683 25 pyrrolo[2,1-cipyrazine hydrochloride are then added to this mixture and the reaction mixture is further stirred for 14 hours, whereby the temperature is gradually allowed to rise to 0. For purposes of working up the reaction mixture is poured into 150 cc. of 2 N hydrochloric acid which contains approximately the same amount of ice, the mixture is stirred well, is then made alkaline with 200 cc. of 2 N sodium carbonate solution and is extracted 5 times with methylene chloride containing some methanol so as to more readily dissolve the 5'-methyl-9,10-dihydro ergocristine. The combined organic phases are first washed with an aqueous ammonia solution, then with a 15% common salt solution, are dried with sodium sulphate and the solvent is removed. A yellow foam is obtained, which is purified by crystallization from ethyl acetate. The re sulting 5'-methyl-9,10-dihydro-ergocristine has an M.P. of 215 (decomp.), c.20=-5.8 (c.=1.0, pyridine).
The S(--)-2-benzyloxy-2-isopropylmalonic acid chlo ride monoethyl ester used as starting material in step (a) may be produced as follows:
(a) 2 -benzyloxy -2 -isopropylmalonic acid diethyl ester-218 g. (1 mol) of 2-hydroxy-2-isopropylmalonic acid diethyl ester are added dropwise while cooling to 20-30° to 6.3 g. (1.3 mols) of a 50% sodium hydride dispersion in paraffin oil. After hydrogen evolution is completed, the reaction mixture is heated to 70° and 205 g. (f) (2R)-5',5'-dimethyl-2'-propylergopeptine.-4.15 g. of (2R,10aS,10bS)-2-amino-5,5-dimethyl-3,6-dioxo-10b hydroxy -2 -propyloctahydro -8H-oxazolo 3,2-alpyrro lo2,1-c) pyrazine-hydrochloride and 6.5 g. of d-lysergic acid chloride hydrochloride are suspended in 50 cc. of absolute methylene chloride, the suspension is cooled to -10° and 35 cc. of absolute pyridine are added dropwise while stirring during the course of 10 minutes. The mix ture is then allowed to react for about 30 minutes at 0 and about 1/2 hours at 20.
The reaction mixture is subsequently worked up in a manner analogous to that described in Example 8, step (f). The resulting crude product is solved in methylene chloride and a small amount of insoluble slurry is filtered ride monoethyl ester.-2-benzyloxy-2-propylmalonic acid diethyl ester is saponified in a manner analogous to that 3,586,683 3. indicated in Example 8, step (b'), except that only 10% excess of lye is used and the resulting monoethyl ester is liberated from the corresponding alkali metal salt at a pH of 3.5. The resulting 2-benzyloxy-2-propyl-malonic acid monoethyl ester is split into the optical antipods with pseudoephedrine, this splitting being effected in a manner analogous to that described in Example 8, step (c) , ex cept that only one third of the indicated amounts of solvent is used in each case, S(-)-2-benzyloxy-2-propyl malonic acid ethyl ester is separated with d-pseudoephed rine and the desired R(--)-2-benzyloxy-2-propylmalonic acid monoethyl ester is converted into a difficultly soluble salt with 1-pseudoephedrine. The salt formed from R(--)-2-benzyloxy-2-propylmalonic acid monoethyl ester and 1 pseudoephedrine is isolated in a manner analogous to that indicated in Example 8, step (c'), is optionally purified by recrystallization and is separated into its components. The so obtained pure R(--)-2-benzyloxy-2-propylmalonic acid monoethyl ester has a rotation value c.20= --6.9 (c.-5, ethanol) and is converted in a manner analogous to that described in Example 8, step (d') into S(--)-2-benzyloxy-2-propylmalonic acid chloride monoethyl ester. S(--)-2-benzyloxy-2-propylmalonic acid chloride mono g. (10 millimoles) of (2R)-5,5-dimethyl-2'-propylergo peptine are added to the resulting colourless suspension, stirring is effected for 10 minutes and 7.1 g. (50 milli moles) of methyl iodide in 10 cc. of absolute ether are added dropwise at -45 to the yellow, green fluorescent turbid solution, whereby a thick mash is formed which, however, again dissolves almost completely after stirring for 45 minutes. Working up is effected by removing the ammonia in a vacuum and working up the residue in a manner analogous to that described in Example 7. The residue is chromatographed on a 35-fold quantity of alumi num oxide, activity II-III. The still impure methylate on product is eluted from the column with methylene chloride containing 0.2% of methanol and is obtained in pure form after recrystallizing several times from methanol: Prac 2. A compound according to claim 1, in which R4 is methyl.
